“First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma” (2025) Journal of Kidney Cancer, 12(2), pp. 27–36. doi:10.15586/jkcvhl.v12i2.387.